

CESCA THERAPEUTICS INC.  
Form 8-K  
December 01, 2017

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 1, 2017**

**CESCA THERAPEUTICS INC.**

(Exact Name of Registrant as Specified in Charter)

Delaware                      333-82900    94-3018487  
(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation)              File Number) Identification No.)

2711  
Citrus  
Road,              95742  
Rancho  
Cordova,  
California  
(Address  
of  
Principal              (Zip  
Executive              Code)  
Offices)

Registrant's telephone number, including area code (949) 753-0624

N/A

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---



**Item 8.01. Other Events.**

On December 1, 2017, Cesca Therapeutics Inc. (the “Company”) closed its public offering of common stock that the Company previously announced on November 29, 2017. At the closing, the Company sold an aggregate of 898,402 shares of its common stock at a price to the public of \$3.00 per share for aggregate offering proceeds of \$2.7 million. After deducting the placement agent's commission and other estimated offering expenses payable by the Company, the net proceeds to the Company in the offering were approximately \$2.33 million. The offering was conducted pursuant to the previously announced placement agency agreement, dated November 29, 2017, between the Company and Dawson James Securities, Inc. (the “Agreement”).

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits*

<u>Exhibit Number</u>	<u>Description</u>
10.1	Placement Agency Agreement, dated November 29, 2017, between Cesca Therapeutics Inc. and Dawson James Securities, Inc.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CESCA  
THERAPEUTICS  
INC.**

By: /s/ Vivian  
Liu  
Name:  
Vivian  
Liu  
Title:  
Chief  
Operating  
Officer

Date: December 1, 2017

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
10.1	<u>Placement Agency Agreement, dated November 29, 2017, between Cesca Therapeutics Inc. and Dawson James Securities, Inc.</u>